ReviewNature reviews. Disease primers2025
Leishmaniasis.
Review in Nature reviews. Disease primers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Peptide-Enabled Nanoplatforms for Malaria and Leishmaniasis: From Intracellular Targeting to Translational Diagnostic Perspectives.ChemMedChem · 2026Review
- Visceral leishmaniasis: an integrated review of resistance mechanisms, host immunometabolism, and next generation therapeutics.Inflammopharmacology · 2026Review
- Epidemiological transitions of Visceral Leishmaniasis in G20 countries: A 33-year retrospective joinpoint and demographic decomposition analysis with 20-year ARIMA projections.PLoS neglected tropical diseases · 2026Article
- Lymphocyte-mediated immune responses to Leishmania infection.Nature reviews. Immunology · 2026Review
- Targeted Molecular Screening ofInternational journal of molecular sciences · 2026Article
- A single-cell transcriptomic atlas of peripheral blood immune cells spanning progressive canine leishmaniosis.iScience · 2026Article
- Chemical Annotation and Biological Evaluation of Prenylated Benzophenone-Rich Fractions fromMolecules (Basel, Switzerland) · 2026Article
- An Immunocompetent Hepatic Organoid Model Reveals Conserved Hepatic Immune Dysregulation DuringInternational journal of molecular sciences · 2026Article
- Genome-wide mapping of replication stress response factors reveals the management of polycistronic transcription, replication initiation, and responses to replication stress in Leishmania.Nucleic acids research · 2026Article
- Immunochemotherapy with Amphotericin B and HisAK70 Vaccine for Cutaneous Leishmaniosis.International journal of molecular sciences · 2026Article
- A Dual-Reporter Fluorescence-Luminescence Assay for Drug Screening in Promastigote and Intracellular Amastigote Stages ofMolecules (Basel, Switzerland) · 2026Article
- Targeting of Leishmania proteins by β-Lapachone derivatives reveals a promising multitarget candidate.Archives of microbiology · 2026Article
- Molecular Diagnosis of Leishmaniasis: Development of a qPCR Assay for Genus Detection and Differentiation ofDiagnostics (Basel, Switzerland) · 2026Article
- Retrospective entomological and eco-epidemiological survey of a leishmaniasis outbreak in southern Spain.One health (Amsterdam, Netherlands) · 2026Article
- Next-Generation Vaccines Against Neglected Diseases: New Promises from Genetically Modified Live-Attenuated Parasites and RNA Vaccines.Microorganisms · 2026Review
- Platelet DKK1 promotes tolerogenic dendritic cells and non-healing responses in cutaneous leishmaniasis.iScience · 2026Article
- Antileishmanial and Immunomodulatory Activity of Paclitaxel and Docetaxel Combined with Miltefosine and Paromomycin.International journal of molecular sciences · 2026Article
- Diagnosis of human cutaneous leishmaniasis: comparison between ITS1-PCR and ITS1-219 next generation sequencing.BMC microbiology · 2026Article
- Post-surgical seroreversion in a case of equine cutaneous leishmaniosis by Leishmania infantum.Veterinary research communications · 2026Article
- Clinical and PET/CT metabolic imaging characteristics across the evolving spectrum of visceral leishmaniasis and associated hemophagocytic lymphohistiocytosis.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is an endemic disease in Asia, Africa, the Americas and Southern Europe caused by Leishmania parasites and transmitted through the bite of female sandflies, resulting in Leishmania replication in macrophages. The condition manifests either as visceral leishmaniasis, a potentially fatal systemic disease that causes persistent fever, enlargement of the liver and spleen (hepatosplenomegaly), and a reduction in almost all blood cells (pancytopenia), or as cutaneous leishmaniasis, characterized by ulcerative or non-ulcerative skin lesions. Disease manifestation and severity are determined by parasite, host and vector characteristics, with a complex immunological interplay. The rK39 rapid diagnostic test is the primary diagnostic method for visceral leishmaniasis, while cutaneous leishmaniasis is commonly diagnosed by microscopy of skin samples. Visceral leishmaniasis and severe forms of cutaneous leishmaniasis are managed by systemic treatment. For localized cutaneous leishmaniasis, treatment involves topical therapies, including cryotherapy, thermotherapy and/or intralesional injections with antimonials. The WHO 2021-2030 roadmap of neglected tropical diseases aims to eliminate visceral leishmaniasis as a public health problem and to achieve enhanced control of cutaneous leishmaniasis. In South Asia, a regional visceral leishmaniasis programme has dramatically reduced the caseload. Eastern Africa has recently launched a similar initiative. Sustainable progress in the control and elimination of leishmaniasis will require better diagnostics, treatment and vector control interventions as well as progress in vaccine development, political commitment, improved surveillance and healthcare services.
Indexed as
Identifiers
41266459What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.